sti-1558 + itraconazole

**sti-1558 + itraconazole** is an investigational **combination** therapy consisting of **olgotrelvir** (sti-1558), an oral small molecule antiviral with dual inhibition of the SARS-CoV-2 main protease (Mpro, also known as 3CLpro) and cathepsin L, plus **itraconazole**, an oral triazole antifungal agent. \n- **Olgotrelvir** works as a standalone SARS-CoV-2 main protease inhibitor, blocking viral replication, and also inhibits host cathepsin L to block viral entry into cells[1][3][5][6]. \n- **Itraconazole** is a well-established systemic antifungal that also inhibits CYP3A4 and has been explored for potential antiviral synergy or for metabolic drug–drug interaction studies, though in this context, no data show a clinical rationale for combining it directly with olgotrelvir except potential for pharmacokinetic study or DDI reference[1][2][3]. \n- STI-1558 is being developed for the treatment of COVID-19; its dual mechanism means it inhibits both viral replication and entry[3][5][6]. \n- The combination (sti-1558 + itraconazole) is not an established or branded Covid-19 therapeutic, and there's no evidence in current literature for this specific regimen as a fixed-dose or co-packaged combination.

Brand names

ovydso

Other names

sti-1558 + itraconazoleolgotrelvir + itraconazole